ImmunoVirotherapy

Oncolytic viruses are engineered to selectively enter and replicate within cancer cells while sparing healthy, non-cancerous cells, thereby performing a dual role in tumor clearance. This process results in the destruction (lysis) of tumor cells and the release of tumor-associated antigens, which can stimulate both innate and adaptive immune responses against the tumor. Such immune activation may occur locally (at the tumor site) or systemically (throughout the body). In many cases, these viruses are further engineered to express immunostimulatory molecules such as GM-CSF or IL-2, which attract and activate immune cells, including T cells and dendritic cells, at the tumor site.

Royan TuCAGene, leveraging cutting-edge knowledge and advanced biotechnological platforms, is developing a new generation of therapeutic solutions. By employing intelligent oncolytic viruses, the company has introduced an innovative immunotherapy approach for aggressive and treatment-resistant cancers, including glioblastoma and gastrointestinal malignancies. At Royan TuCAGene, we are also advancing the production of biosimilar products in alignment with globally recognized reference models, with the aim of improving patient access to effective and affordable therapies. All research, development, and manufacturing processes within the company are conducted under the highest international standards of GMP, GLP, and GDP to ensure the safety, efficacy, and quality of its products and services.